NCT00955084

Maintenance Study on the Long Term Safety of XL999

A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Symphony Evolution, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows: * To evaluate tumor response after long term repeat administration of XL999 in two subjects rolled over from other XL999 studies. * To characterize the long term safety and tolerability of XL999 after repeat administration in two subjects rolled over from other XL999 studies. * To characterize the long term effects of XL999 on cardiac function after repeat administration in two subjects rolled over from other XL999 studies.

Conditions

• Advanced Malignancies

Interventions

Type	Name	Description
DRUG	XL999	XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL

Timeline

• Start date: 2008-08-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2009-08-07
• Last updated: 2010-09-24

Locations

2 sites across 1 country: United States